Stéphane Bancel Net Worth, Family Wife【 Moderna Bio 】House, Parents

Name Stéphane Bancel

Birthday / Age / Date of Birth / How old is Stéphane Bancel Born on July 20, 1972. As of 2024, he is around 52 years old.

Wikipedia Biography / Profile Background

Introduction :

Stéphane Bancel is the Chief Executive Officer (CEO) of the American biotechnology company, Moderna Therapeutics. A French billionaire, Bancel has emigrated from his home country of France to the USA. He now resides in Boston, Massachusetts, United States of America.
As the founding CEO and President at Moderna Therapeutics, Stéphane has around 9% ownership share in the firm. Moderna has produced one of the world’s leading successful COVID-19 vaccines.

Personal Life, Parents and Family Details :

Born on July 20, 1972, in Marseille, France, Stephane has two children.
Apart from his two children, there is no information available about his family or personal life.

Early Life and Education :

Stéphane’s fierce interest in science and math led him to an early exploration into engineering. As a kid, Stéphane always wanted to work in technology and often tinkered with computers.
During high school, Stéphane nurtured an interest in biology and chemistry.

Stéphane attended Centrale Supelec of Paris-Saclay University (formerly known as Ecole Centrale Paris) from 1992 to 1995. He graduated with a Master of Engineering degree, majoring in Chemical and Biomolecular Engineering.
Stéphane also has an M.Sc. in Chemical Engineering from the University of Minnesota. He studied biochemical engineering and published a thesis on ‘Topographical Imaging of Macroporous microcarriers’.
In 1999, Bancel enrolled at Harvard Business School. He graduated in 2000 with the prestigious Harvard MBA.

Career, Job, Salary and Net Worth :

In the early stages of his career, Bancel worked in various roles at the American pharmaceutical firm, Eli Lilly and Company. He took on roles like Executive Director, Global Manufacturing Strategy and Supply Chain and as Managing Director, Belgium from July 2000 to March 2006.
Later, Stéphane started working at French diagnostics company BioMérieux (founded by fellow French billionaire Alain Mérieux) as an Asia-Pacific Sales and Marketing Director. In 2007, Bancel was appointed the CEO of BioMérieux. Bancel remained in the role for five years, from January 2007 to October 2011. As the company’s CEO, he expanded BioMérieux’s operations to 5,000+ employees and increased sales to billions of dollars.

Moderna Therapeutics (founded in 2010), a Cambridge, Massachusetts-based biotech firm, went public in December 2018. Moderna develops vaccines and drugs using messenger RNA (mRNA) and gained widespread recognition after it developed a successful vaccine for COVID-19. Since March 2011, Stéphane has served as a member of Moderna’s board of directors and as Moderna’s CEO since October 2011.
Currently, Stéphane also serves on the board of directors of Indigo Qiagen N.V.
Additionally, he is also a trustee for the Museum of Science in Boston and a Venture Partner at Flagship Pioneering.

Interesting Facts, Height and Trivia :

Stéphane’s stake of about 9% in Moderna became worth over $1 billion in April 2020 after news of imminent phase 2 human trials for its potential COVID-19 vaccine. Moderna was the first firm to begin human trials for the COVID-19 vaccine in March 2020.
Currently, Stéphane’s net worth is assumed to be over US$4.5 billion.

As per his Forbes profile, Stéphane has transformed Moderna Therapeutics from a one-person shop to a market player that rapidly revolutionized the biotech industry.
From 2009 to 2010, Stéphane had received more than 20 calls from leading biotech companies requesting him to join and lead their respective companies.
Under Stéphane’s leadership, Moderna Therapeutics’ academic co-founders published a paper in the journal Nature Biotechnology in September 2013. The paper showed helping a mouse through myocardial infarction. It repaired damaged heart tissue due to mRNA’s capability to stimulate blood vessel growth.

As per a New York Times report, Moderna was awarded $25 million by the U.S. government’s Defense Advanced Research Projects Agency (DARPA) to develop mRNA to combat biological threats and infectious diseases in October 2013.
In March 2020, Stéphane disclosed in a statement that Moderna was primarily focused on safety aspects while conducting clinical programs for the COVID-19 vaccine. He assured the public that humanity would survive the pandemic together with Moderna’s mRNA-1273 vaccine.
While giving an interview to Harvard Innovation Labs, Stéphane attributed his success as an executive to his liberal arts education in France despite his deep focus on life sciences. He added that delving into geography as a youngster led him to better understand the global economy and market dynamics.

Leave a Reply Cancel reply